Conference Day One - Monday, October 15, 2012

As a courtesy, we are making available last year’s agenda for you to review.

7:30 Networking Breakfast & Conference Registration

Networking Breakfast & Conference Registration

8:45 Welcoming Remarks

Welcoming Remarks:

Jenny Andreyeva
Executive Director
BioNetwork

8:50 Chairperson's Opening Remarks

Linda Pullan, PhD, Pullan Consulting

Chairperson's Opening Remarks

Linda Pullan, PhD

, Pullan Consulting

Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects partnering. Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has over 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca. She contributed to and led teams that put the multi-billion dollar antipsychotic Seroquel and [read more]

9:00 Partnering In The New Reality: Balancing Risk With Necessity

Robert Bagdorf, Vice President, Biopharmaceuticals Search and Evaluation,Worldwide Business Development, Pfizer
Gayle M. Mills, M.B.A., Chief Business Officer, Symphogen A/S
Eric D. Malek, Vice President of Corporate Development, Threshold Pharmaceuticals
Stephen B. Thau, Principal, Morrison Foerster

In an environment where big pharma is hungry for the best deals while trying to be more risk averse, they are placed into a tough position due to the increased premiums which they need to pay to win over key partnerships. This session discusses whether there has been a power shift and what impact the financial struggles within big pharma are having. What is driving the recent biotech rejections of big pharma offers? Is this bound to occur with a greater number of larger, late stage biotechs and does this leave the early stage biotechs more vulnerable to mergers, though increasingly of interest due to their lower price points?

Moderated by: Stephen B. Thau, Partner, Morrison Foerster

Panelists Include:

Robert Bagdorf

Vice President, Biopharmaceuticals Search and Evaluation,Worldwide Business Development, Pfizer

Robert Bagdorf leads Pfizer’s Search and Evaluation business development group. This function is responsible for company outreach, asset identification, and due diligence activities for the Primary Care, Specialty Care and Oncology Business Units. He has over 10 years experience in the identification and evaluation of licensing and M&A opportunities on both a glo [read more]

Gayle M. Mills, M.B.A.

Chief Business Officer, Symphogen A/S

Gayle has successfully led the strategic and business development activities of a number of premier pharmaceutical, biotech and diagnostic companies, including Symphogen A/S, Abgenix, Roche Bioscience, and Affymax N/V. She began her career in pharmaceutical sales and marketing at Sandoz. Gayle currently holds the position of Chief Business Officer of Symphogen A/S a Danish corporation focused on t [read more]

Eric D. Malek

Vice President of Corporate Development, Threshold Pharmaceuticals

Eric Malek joined Threshold as Vice President, Corporate Development in 2010 and in early 2012 executed a $550M global co-development and co-commercialization agreement with Merck Serono for Threshold's clinical stage hypoxia activated pro-drug TH-302. He is a member of the joint steering committee and responsible for alliance management. Prior to joining Threshold he led corporate development at [read more]

Stephen B. Thau

Principal, Morrison Foerster

Stephen Thau has been recognized as one of the top biotech attorneys in California. His practice focuses on the representation of life science, medical device, and other technology companies in transactional matters, including merger and acquisition, licensing and collaborations, strategic alliances, public offerings and equity and deb [read more]

10:00 Combatting The Stagnant Innovation Environment

Claude Nicaise, Senior Vice President Strategic Development and Global Regulatory Affairs, Alexion
Kevin Skol, Director of Business Development, Isis Pharmaceuticals
James Hattersley, Vice President of Business Development, Sun Pharmaceutical Industries
Rekha Hemrajani, Vice President, Head of Licensing and M&A, Onyx Pharmaceuticals

Industry wide there have been many discussions as to how biotechs and pharma can combat the stagnation which is occurring. Companies feel a dire need for innovation, which is not being encouraged. VC’s skewing away from funding key developments within biotechs due to necessary investment amounts and associated risk is leaving the biotechs strapped for cash and pharmas scurrying to find innovative products to fill their pipelines. How should the industry cope with this dilemma, what factors are at play, why is this happening, and what is each party’s role? We will discuss how regulatory actions affect innovation and how to overcome the roadblocks.

Panelists Include:

Claude Nicaise

Senior Vice President Strategic Development and Global Regulatory Affairs, Alexion

Dr. Claude Nicaise is Senior Vice President of Strategic Product Development and Global Regulatory Affairs, a position he has held since joining the company in 2008. In this role, Dr. Nicaise is responsible for the company's regulatory activities worldwide as Alexion develops new products and prepares for entry into new markets.Prior to joining Alexion, Dr. Nicaise worked for Bristol-Myers Squibb [read more]

Kevin Skol

Director of Business Development, Isis Pharmaceuticals

Kevin Skol leads the business development activities at Isis Pharmaceuticals. Kevin is primarily responsible for implementing Isis’ innovative partnering structures. Prior to Isis, Kevin was a marketing director, neuroscience at Valeant Pharmaceuticals leading its migraine franchise. Kevin also spent several years in business development at Valeant where the team completed numer [read more]

James Hattersley

Vice President of Business Development, Sun Pharmaceutical Industries

James Hattersley has over 24 years of successful leadership experience in biotechnology & pharmaceutical life sciences. From 1986 to 1995 Jim was responsible for drug delivery and NCE research at Alza Corporation and Abbott Laboratories. Since 1995 Jim has led strategic business growth including execution of several transactions of significant value at Eurand, Antares, and Sun Phar [read more]

Rekha Hemrajani

Vice President, Head of Licensing and M&A, Onyx Pharmaceuticals

Rekha Hemrajani has had an eighteen year career focused on the health care and biotech industries both on the financial/deal-making side as well as the operational side of companies. She is currently Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals, Previously, she was Vice President of Business Development at Exelixis and has been involved in raising over $800 mil [read more]

11:00 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity.

Sponsored by Merck

11:30 Alternative Funding: Sanofi And Third Rock Ventures Launch Warp Drive Bio

Bernard Davitian, VP, Deputy Corporate Licenses, Strategy and Business Development, Sanofi
Alexis Borisy, CEO, Warp Drive Bio / Partner, Third Rock Ventures,

This case study will examine Warp Drive Bio, which launched with $125M in funding. Funding was provided by Third Rock Ventures - which will discuss its innovative model of investing along with Sanofi- who will tell us why they chose Warp Drive Bio and what the structure of their partnership entails. You will hear about what is driving the success of their partnership and how you can add to your own.

Bernard Davitian

VP, Deputy Corporate Licenses, Strategy and Business Development, Sanofi

Mr. Bernard Davitian has about 25 years of management, business and corporate finance experience in the life sciences and biotech industry, marked by many fund raising and M&A closed. His track record includes, among others, the successful IPO of transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a up to WBR [read more]

Alexis Borisy

CEO, Warp Drive Bio / Partner, Third Rock Ventures,

Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interi [read more]

12:00 Securing Funding: Managing Relationships With VC’s

Michael Powell, Managing General Partner, Sofinnova Ventures
John Gustofson, Director of Strategic Partnering and Business Development, AstraZeneca
Doug Treco, President and CEO , Ra Pharmaceuticals

Funding for biotechs has always been challenging to attain, but even more so in today’s environment. This session will open up a discussion as to how increased exit times as well as investment stringencies affect both the venture capitalists and biotechs. With both sides of the partnerships under pressure, what is the best approach to ensure efficient and successful relationships between VC’s and biotechs? What are venture capitalists looking for and how can your company attract their investment? How should a company relying on VC funding prepare for the next steps, particularly the possibility of a merger or IPO?

Panelists Include:

Michael Powell

Managing General Partner, Sofinnova Ventures

Mike has more than 25 years of pharmaceutical development experience, and has focused interest in clinical-stage product companies, particularly in oncology. He joined Sofinnova Ventures as a General Partner in 1997. Prior to becoming a venture capitalist, Mike worked on 20 different clinical products, and authored almost 100 papers and books including a 1,000–page treatise on v [read more]

John Gustofson

Director of Strategic Partnering and Business Development, AstraZeneca

John Gustofson is a Director of Strategic Partnering and Business Development at AstraZeneca. In his current position, John is responsible for identifying, evaluating and negotiating early preclinical to late stage clinical opportunities with a focus on Oncology. John has 15+ years professional experience with early stage biotechnology and pharmaceutical industries. In addition, John spent approxi [read more]

Doug Treco

President and CEO , Ra Pharmaceuticals

Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc),a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug estab [read more]

12:30 Networking Lunch

Networking Lunch

1:45 Innovation Spotlight – Using Software Analytics To Monitor Trends In Business Development And Licensing

David Greenwald, Co-founder & Managing Director, Relay Technology Management

Innovation Spotlight – Using Software Analytics To Monitor Trends In Business Development And Licensing

David Greenwald

Co-founder & Managing Director, Relay Technology Management

Dr. Greenwald is a co-founder of Relay Technology Management, Inc. and currently serves as Managing Director. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Centerin Silver Spring, MD. Dr. Greenwald worked with the Food and Drug Administration (FDA) on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) [read more]

2:00 BioNetwork Round Tables:

Luke Duster, Principal , Capital Royalty
Jeremy Broadis, VP, Global Commercial Partnering , Quintiles

Here is your chance to sit down with your peers and engage in candid, interactive discussions with industry experts. Each topic will be led by a table moderator - a subject matter expert - who will facilitate the idea exchange among participants. Topics will rotate every 30 minutes.

Topics Include:

Alternative sources of capital: Using royalty financing, structured debt, and revenue interest financings to raise non-dilutive capital

Moderated by: Luke Duster, Principal, Capital Royalty
Balancing risk & reward of various late stage partnership models

Moderated by: Jeremy Broadis, VP Global Commercial Partnering, Quintiles
Partnering and Expansion in South East Asia and South America for the biosimilars market
Shifting focuses: opportunities and obstacles in the development of drugs and devices for rare diseases
How to secure available grants and funding especially for underfunded therapeutic areas
Is the industry facing an emerging power shift and how will this influence innovation strategies?
Safety vs. Efficacy: how to approach the pendulum shift in the regulatory environment
Industry consolidation and how to prevent it by sourcing innovation
Clinical trial opportunities in Eastern Europe

If you are interested in moderating a Roundtable contact Rachel Tosi at 646- 200-7524 or Rachel.Tosi@wbresearch.com

Luke Duster

Principal , Capital Royalty

Luke Düster is a Principal at Capital Royalty, a healthcare focused investment management firm. Capital Royalty works directly with leading healthcare companies, research institutions, and inventors to provide customized financing structures to meet their unique needs. Since joining Capital Royalty in 2009, Mr. Düster has focused on investment sourcing, performing [read more]

Jeremy Broadis

VP, Global Commercial Partnering , Quintiles

Jeremy’s career in Healthcare spans over 21 years. His current role at Quintiles is leading a global business development team focused on the creation of innovative commercial partnering solutions for biotechnology companies which integrate flexible operational resource, expertise and non-traditional finance. Within his 14 year career at Quintiles, Jeremy has also worked in mark [read more]

3:30 Refreshment Break & Networking Opportunity

Refreshment Break & Networking Opportunity

4:00 Prospective Structures For Funding Operations In Companies Across The Board

Christopher Seaton, SVP Global Transactions, Bayer Healthcare
Carolyne Zimmermann, Global Head Search, Evaluations & Negotiations, Novartis Pharmaceuticals
Jones Woody Bryan, Vice President of Business Development and Licensing, Supernus Pharmaceuticals
Fredrik Wiklund, Head of Corporate Strategy & Development, Celladon Corporation

Royalty monetization is an increasingly popular source of funding for companies to finance R&D, clinical trials, and developments. What is necessary to create funds using this strategy and how early can monetization take place? Co-development is also increasing in popularity since it leverages the risk on the part of the pharma and promises for more efficiency from and returns to the biotech. Another angle to examine is the corporate ventures groups within pharmaceutical companies and what opportunities they offer as well as how the approach to them has changed. How do we navigate through the complexities of these deals?

Panelists Include:

Christopher Seaton

SVP Global Transactions, Bayer Healthcare

Mr. Seaton is responsible for major transactions in Bayer HealthCare, including licensing, product acquisition, divestitures and out-licensing. Mr. Seaton is based in the United States with direct reports in the USA and Germany. Mr. Seaton earned both his Masters of Business Administration and his undergraduate degree from McMaster University, Hamilton, Ontario, Canada. Mr. Seaton has had experien [read more]

Carolyne Zimmermann

Global Head Search, Evaluations & Negotiations, Novartis Pharmaceuticals

Carolyne Zimmermann is an Executive Director in the Global Business Development and Licensing Group at Novartis Pharmaceuticals. In her current role as the Head of Search, Evaluation and Negotiations, she is responsible for securing strategic assets to expand the Critical Care Franchise pipeline and portfolio. She works closely with her medical and marketing colleagues to shape and implement the l [read more]

Jones Woody Bryan

Vice President of Business Development and Licensing, Supernus Pharmaceuticals

Jones W. Bryan, PhD, has served as Vice President of Business Development since 2005. From 2000 to 2005, he served as Vice President of Business Development for Shire Laboratories Inc. Dr. Bryan was Director of Business Development for Pharmaceutics and Clinical Supply Manufacturing for AAI. He began his career with Schering-Plough in Pharmaceutics and Formulation Development. Dr. Bryan earned his [read more]

Fredrik Wiklund

Head of Corporate Strategy & Development, Celladon Corporation

Mr. Wiklund has over 15 years of biopharmaceutical industry experience, currently serving as the Head of Corporate Development of Celladon Corporation. Celladon’s products are first-in-class drugs that target the key enzyme deficiency in cardiomyocytes of heart failure patients, SERCA2a. Celladon has raised an excess of $125 million in venture capital. Current investors include [read more]

5:00 Industry Shifts: The Evolving Nature Of Biotechs - An Amgen Case Study

Kal Patel, Executive Director, Strategy & Corporate Development, Amgen

In an industry of constant changes and consolidation, Amgen has excelled in differentiating itself from the pack. Amgen’s activity has always been noted, but more recently it has been behaving increasingly like a big pharma – from paying out dividends to making investments overseas. Kal Patel will discuss the strategy Amgen has taken on to distinguish itself and its operations, keeping it ahead of biotech, and industry standards.

Kal Patel

Executive Director, Strategy & Corporate Development, Amgen

Kal Patel, MD, is Executive Director of Strategy & Corporate Development. Prior to joining Amgen, Kal was in a field leadership role at Novartis and was a Principal at the Boston Consulting Group. Kal has worked extensively across the health care value chain in both the U.S. and Europe. He holds an MD and MBA, both from the University of Chicago.

5:30 Networking Cocktail Reception

Networking Cocktail Reception






	Interested In Sponsoring?
	Send me email updates






	Interested In Sponsoring?
	Send me email updates

Conference Day One - Monday, October 15, 2012

As a courtesy, we are making available last year’s agenda for you to review.

Linda Pullan, PhD , Pullan Consulting

Robert Bagdorf Vice President, Biopharmaceuticals Search and Evaluation,Worldwide Business Development, Pfizer

Gayle M. Mills, M.B.A. Chief Business Officer, Symphogen A/S

Eric D. Malek Vice President of Corporate Development, Threshold Pharmaceuticals

Stephen B. Thau Principal, Morrison Foerster

Claude Nicaise Senior Vice President Strategic Development and Global Regulatory Affairs, Alexion

Kevin Skol Director of Business Development, Isis Pharmaceuticals

James Hattersley Vice President of Business Development, Sun Pharmaceutical Industries

Rekha Hemrajani Vice President, Head of Licensing and M&A, Onyx Pharmaceuticals

Bernard Davitian VP, Deputy Corporate Licenses, Strategy and Business Development, Sanofi

Alexis Borisy CEO, Warp Drive Bio / Partner, Third Rock Ventures,

Michael Powell Managing General Partner, Sofinnova Ventures

John Gustofson Director of Strategic Partnering and Business Development, AstraZeneca

Doug Treco President and CEO , Ra Pharmaceuticals

David Greenwald Co-founder & Managing Director, Relay Technology Management